Verastem, Inc. (VSTM): Price and Financial Metrics
VSTM Price/Volume Stats
|Current price||$8.13||52-week high||$15.18|
|Prev. close||$8.32||52-week low||$3.47|
|Day high||$8.47||Avg. volume||184,845|
|50-day MA||$9.84||Dividend yield||N/A|
|200-day MA||$7.44||Market Cap||205.29M|
VSTM Stock Price Chart Interactive Chart >
Verastem, Inc. (VSTM) Company Bio
Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.
VSTM Latest News Stream
|Loading, please wait...|
VSTM Latest Social Stream
View Full VSTM Social Stream
Latest VSTM News From Around the Web
Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
BOSTON, September 28, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the presentation of scientific background and clinical trial updates on the avutometinib and defactinib programs at the 5th Annual RAS-Targeted Drug Development Summit in Boston, Massachusetts. The updates are part of two oral presentations by Jonathan Pachter, PhD, Chief Scientific Officer and Louis Denis, MD, Chief Medical Off
BOSTON, September 05, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing.
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
BOSTON, August 28, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has entered into a discovery and development collaboration with GenFleet Therapeutics ("GenFleet") to advance three oncology discovery programs targeting RAS pathway-driven cancers.
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, August 08, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress.
VSTM Price Returns